Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.
Image: Tessa partners with Vineti on cancer immunotherapies. Photo: courtesy of dream designs/FreeDigitalPhotos.net.
Subscribe to our email newsletter
Tessa Therapeutics (Tessa), an international clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, is a leading developer of personalized T cell therapies for solid tumors, including head and neck cancers and cervical cancer.
Vineti provides the leading digital software platform to align and manage the complex personalized cell therapy process, safely and efficiently.
The goal of the partnership is to scale Tessa’s therapies world-wide in a safe and efficient manner, supporting both late clinical stage therapies approaching commercialization and early-phase therapies progressing through various clinical stages. Tessa, headquartered in Singapore, brings international expertise through both its Asia operations and its global treatment network.
Tessa’s Virus-Specific T cell (VST) technology is showing compelling results and an excellent safety profile in the treatment of cancer.
The company is currently conducting a multi-center Phase III trial targeting nasopharyngeal cancer, and a Phase I trial targeting cervical cancer and oropharyngeal cancer, set to move into Phase II in 2019. In addition, Tessa is developing a broad pipeline of pre-clinical therapies targeting major cancers such as liver and lung using its VST platform.
Tessa chief business officer Jennifer Butler said: “As a team of industry experts who care deeply about patient care, Tessa understands the current challenges in cell therapy and is addressing them proactively by partnering with Vineti.
“By running our therapies on the Vineti platform, we are taking an important step towards global commercial readiness.”
Vineti’s platform will support Tessa as it builds its pipeline of therapies and prepares for commercialization, with a focus on providing a digital orchestration platform to track, trace, align, and simplify the complex journey that underlies each therapy’s personalized operations and logistics chain.
Vineti is now supporting patients and clinicians in more than 65 leading medical centers, and is rapidly expanding to Asia-Pacific and Europe.
Vineti CEO Amy DuRoss said: “Vineti is honored to support Tessa in its work to develop transformative, critically-needed therapies.
“The Vineti platform is designed to support innovative therapies as they evolve and scale. Therapeutic advances against solid tumors will make a real difference for even more patients, and we are very excited to help Tessa scale their treatments globally.”
Vineti is the first cloud-based software platform to safely and efficiently move patient-based personalized therapies into mainstream medicine at scale. The Vineti platform – configurable, cloud-based, secure and scalable – brings the best of enterprise software to next-generation pharmaceutical science.
Vineti’s solution aligns, manages, integrates and simplifies all the major steps and stakeholders in the inherently complex cell and gene therapy process, helping everyone from health care providers to biopharma and manufacturers exert efficiency and control to optimize the patient’s therapy journey.
This announcement follows Tessa’s recent research collaboration with St. Jude, and Vineti’s strategic teaming agreement with Deloitte.
Source: Company Press Release
